Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Directional PSA Versus STN DBS for TD-PD

NCT: NCT07700862 · RECRUITING

NCT IDNCT07700862
StatusRECRUITING
Start Date2026-07-01
Completion2029-06
SponsorRuijin Hospital (OTHER)
First posted
Last updated

Brief Summary

The aim of this study is to compare the effectiveness of the deep brain stimulation in the posterior subthalamic area (PSA) versus the subthalamic nucleus (STN) using directional lead for the treatment of tremor-dominant Parkinson's disease (PD) in a randomized, double-blinded, cross-over manner.

Frequently Asked Questions

What is Directional PSA Versus STN DBS for TD-PD?

Directional PSA Versus STN DBS for TD-PD is a clinical trial registered under NCT07700862. Current status: RECRUITING.

What is the status of NCT07700862?

The current status of NCT07700862 (Directional PSA Versus STN DBS for TD-PD) is: RECRUITING.

When did Directional PSA Versus STN DBS for TD-PD start?

Directional PSA Versus STN DBS for TD-PD started on 2026-07-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑